This paper is in the following e-collection/theme issue:

Neurology and Neurosciences (185) Electronic/Mobile Data Capture, Internet-based Survey & Research Methodology (834)

Published on in Vol 4, No 1 (2015): Jan-Mar

This is a member publication of PatientsLikeMe, Cambridge, USA

Preferred Features of Oral Treatments and Predictors of Non-Adherence: Two Web-Based Choice Experiments in Multiple Sclerosis Patients

Preferred Features of Oral Treatments and Predictors of Non-Adherence: Two Web-Based Choice Experiments in Multiple Sclerosis Patients

Preferred Features of Oral Treatments and Predictors of Non-Adherence: Two Web-Based Choice Experiments in Multiple Sclerosis Patients

Authors of this article:

Paul Wicks1 Author Orcid Image ;   David Brandes2 Author Orcid Image ;   Jinhee Park3 Author Orcid Image ;   Dimitri Liakhovitski4 Author Orcid Image ;   Tatiana Koudinova4 Author Orcid Image ;   Rahul Sasane3 Author Orcid Image
Article Authors Cited by (30) Tweetations (2) Metrics

Journals

  1. Ravoire S, Lang M, Perrin E, Audry A, Bilbault P, Chekroun M, Demerville L, Escudier T, Guéroult-Accolas L, Guillot C, Malbezin M, Maugendre P, Micallef J, Molimard M, Montastruc F, Pierron E, Reichardt L, Thiessard F. Advantages and limitations of online communities of patients for research on health products. Therapies 2017;72(1):135 View
  2. Visser L, Louapre C, Uyl-de Groot C, Redekop W. Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders 2020;39:101929 View
  3. Nicholas J, Edwards N, Edwards R, Dellarole A, Grosso M, Phillips A. Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis. BMC Neurology 2020;20(1) View
  4. Rahimi F, Rasekh H, Abbasian E, Peiravian F, Etemadifar M, Ashtari F, Sabzghabaee A, Amirsadri M, Weber M. Patient preferences for Interferon-beta in Iran: A discrete choice experiment. PLOS ONE 2018;13(3):e0193090 View
  5. Wynn D. Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use. Multiple Sclerosis International 2019;2019:1 View
  6. Bottomley C, Lloyd A, Bennett G, Adlard N. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis. Journal of Medical Economics 2017;20(8):863 View
  7. Ravoire S, Lang M, Perrin E, Audry A, Bilbault P, Chekroun M, Demerville L, Escudier T, Guéroult-Accolas L, Guillot C, Malbezin M, Maugendre P, Micallef J, Molimard M, Montastruc F, Pierron E, Reichardt L, Thiessard F. Intérêts et limites des communautés virtuelles de patients pour la recherche sur les produits de santé. Therapies 2017;72(1):125 View
  8. Johnson K, Zhou H, Lin F, Ko J, Herrera V. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year. Journal of Managed Care & Specialty Pharmacy 2017;23(8):844 View
  9. Mansfield C, Thomas N, Gebben D, Lucas M, Hauber A. Preferences for Multiple Sclerosis Treatments. International Journal of MS Care 2017;19(4):172 View
  10. Jonker M, Donkers B, Goossens L, Hoefman R, Jabbarian L, de Bekker-Grob E, Versteegh M, Harty G, Wong S. Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options. Medical Decision Making 2020;40(2):198 View
  11. Webb E, Meads D, Eskytė I, Ford H, Bekker H, Chataway J, Pepper G, Marti J, Okan Y, Pavitt S, Schmierer K, Manzano A. The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments. The Patient - Patient-Centered Outcomes Research 2020;13(5):583 View
  12. Kremer I, Evers S, Jongen P, van der Weijden T, van de Kolk I, Hiligsmann M, Aktas O. Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst Scaling. PLOS ONE 2016;11(11):e0164862 View
  13. Kremer I, Evers S, Jongen P, Hiligsmann M. Comparison of preferences of healthcare professionals and MS patients for attributes of disease‐modifying drugs: A best‐worst scaling. Health Expectations 2018;21(1):171 View
  14. Hincapie A, Penm J, Burns C. Factors Associated with Patient Preferences for Disease-Modifying Therapies in Multiple Sclerosis. Journal of Managed Care & Specialty Pharmacy 2017;23(8):822 View
  15. Poulos C, Wakeford C, Kinter E, Mange B, Schenk T, Jhaveri M. Patient and physician preferences for multiple sclerosis treatments in Germany: A discrete-choice experiment study. Multiple Sclerosis Journal - Experimental, Translational and Clinical 2020;6(1) View
  16. Webb E, Meads D, Eskyte I, King N, Dracup N, Chataway J, Ford H, Marti J, Pavitt S, Schmierer K, Manzano A. A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis. The Patient - Patient-Centered Outcomes Research 2018;11(4):391 View
  17. Lin P, Saret C, Neumann P, Sandberg E, Cohen J. Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study. PharmacoEconomics 2016;34(12):1255 View
  18. Alroughani R, Inshasi J, Al-Asmi A, Alkhabouri J, Alsaadi T, Alsalti A, Boshra A, Canibano B, Ahmed S, Shatila A. Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf Region. Neurology and Therapy 2020;9(2):265 View
  19. Fox E, Vieira M, Johnson K, Peeples M, Bensimon A, Signorovitch J, Herrera V. Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3 years: a retrospective US claims database analysis. Journal of the Neurological Sciences 2019;398:163 View
  20. Poulos C, Kinter E, van Beek J, Christensen K, Posner J. PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE. International Journal of Technology Assessment in Health Care 2018;34(4):425 View
  21. Rahn A, Solari A, Beckerman H, Nicholas R, Wilkie D, Heesen C, Giordano A. “I Will Respect the Autonomy of My Patient”. International Journal of MS Care 2020;22(6):285 View
  22. Ngorsuraches S, Poudel N. Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. Expert Review of Pharmacoeconomics & Outcomes Research 2021;21(2):183 View
  23. Visser L, Huls S, Uyl-de Groot C, de Bekker-Grob E, Redekop W. An implantable device to treat multiple sclerosis: A discrete choice experiment on patient preferences in three European countries. Journal of the Neurological Sciences 2021;428:117587 View
  24. Rice D, Kaplan T, Hotan G, Vogel A, Matiello M, Gillani R, Hutto S, Ham A, Klawiter E, George I, Galetta K, Mateen F. Electronic pill bottles to monitor and promote medication adherence for people with multiple sclerosis: A randomized, virtual clinical trial. Journal of the Neurological Sciences 2021;428:117612 View
  25. Simblett S, Pennington M, Quaife M, Theochari E, Burke P, Brichetto G, Devonshire J, Lees S, Little A, Pullen A, Stoneman A, Thorpe S, Weyer J, Polhemus A, Novak J, Dawe-Lane E, Morris D, Mutepua M, Odoi C, Wilson E, Wykes T. Key Drivers and Facilitators of the Choice to Use mHealth Technology in People With Neurological Conditions: Observational Study. JMIR Formative Research 2022;6(5):e29509 View
  26. Burtchell J, Clemmons D, Clemmons J, Sabutis T, Rosenberg A, Graves J, Sweeney M, Kramer J, Ziehn M, Brown B, Weiss J, Obeidat A. A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies. Neurology and Therapy 2022;11(3):955 View
  27. Sabsabi S, Mikhael E, Jalkh G, Macaron G, Rensel M. Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence. Patient Preference and Adherence 2022;Volume 16:1307 View
  28. Abdelraheem O, Sami D, Salama M. Online Health Communities: an alternative feasible data registry tool for developing countries. Health Research Policy and Systems 2023;21(1) View
  29. Webb E, Meads D, Eskytė I, Ford H, Bekker H, Chataway J, Pepper G, Marti J, Okan Y, Pavitt S, Schmierer K, Manzano A. Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices. The Patient - Patient-Centered Outcomes Research 2023;16(5):457 View
  30. Oreja-Guevara C, Martínez-Yélamos S, Eichau S, Llaneza M, Martín-Martínez J, Peña-Martínez J, Meca-Lallana V, Alonso-Torres A, Moral-Torres E, Río J, Calles C, Ares-Luque A, Ramió-Torrentà L, Marzo-Sola M, Prieto J, Martínez-Ginés M, Arroyo R, Otano-Martínez M, Brieva-Ruiz L, Gómez-Gutiérrez M, Rodríguez-Antigüedad A, Galán Sánchez-Seco V, Costa-Frossard L, Hernández-Pérez M, Landete-Pascual L, González-Platas M, Meca-Lallana J. Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management. Therapeutic Advances in Neurological Disorders 2024;17 View